Evidence map›Paper›PMID 38785463›Full record

ArticleCurrent oncology (Toronto, Ont.)2024

Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for

Amanda Jane Williams Gibson, Michelle Liane Dean, Ishjot Litt, Adrian Box, Winson Y Cheung, Vishal Navani

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. First-line osimertinib in advancedESMO real world data and digital oncology · 2026
    Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Amanda Jane Williams GibsonDepartment of Oncology, Cumming School of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, AB T2N 4N1, Canada.ORCID 0000-0002-7282-5744
Michelle Liane DeanDepartment of Oncology, Cumming School of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, AB T2N 4N1, Canada.
Ishjot LittDepartment of Oncology, Cumming School of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, AB T2N 4N1, Canada.
Adrian BoxAlberta Precision Laboratories, Molecular Pathology Laboratory, 3535 Research Road NW, Calgary, AB T2L 2K8, Canada.
Winson Y CheungDepartment of Oncology, Cumming School of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, AB T2N 4N1, Canada.
Vishal NavaniDepartment of Oncology, Cumming School of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, AB T2N 4N1, Canada.ORCID 0000-0002-6795-009X

Funding

Philanthropic donation to the Glans-Look Lung Cancer Research Database N/A
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AcrylamidesAniline CompoundsErbB ReceptorsLung NeoplasmsMutationAgedAged, 80 and overAntineoplastic AgentsCarcinoma, Non-Small-Cell LungDisease ProgressionFemaleHumansIndolesMaleMiddle AgedProtein Kinase InhibitorsAcrylamidesAniline CompoundsAntineoplastic AgentsEGFR protein, humanErbB ReceptorsIndolesosimertinibProtein Kinase InhibitorsPyrimidinesEGFR mutation-positivefirst-line osimertiniboutcomespost-progressionreal-world

Identifiers

PMID38785463
PMCPMC11120125

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.